Reactive oxygen species and melanoma: an explanation for gender differences in survival?
- PMID: 20218981
- DOI: 10.1111/j.1755-148X.2010.00694.x
Reactive oxygen species and melanoma: an explanation for gender differences in survival?
Abstract
Epidemiological research consistently shows a female advantage in melanoma survival. So far, no definite candidate for the explanation of this phenomenon has emerged. We propose that gender differences in oxidative stress caused by radical oxygen species (ROS) underlie these survival differences. It is known that males express lower amounts of anti-oxidant enzymes, resulting in more oxidative stress than females. The primary melanoma environment is characterized by high ROS levels, from exogenous sources as well as ROS production within melanoma cells themselves. ROS are known to be able to promote metastasis through a wide variety of mechanisms. We hypothesize that the higher levels of ROS in men enhance selection of ROS-resistance in melanoma cells. Subsequently, ROS can stimulate the metastatic potential of melanoma cells. In addition, due to the lower anti-oxidant defenses in men, ROS produced by melanoma cells cause more damage to healthy tissues surrounding the tumor, further stimulating metastasis. Therefore, ROS may explain the observed differences between males and females in melanoma survival.
Similar articles
-
Reactive oxygen species in melanoma and its therapeutic implications.Melanoma Res. 2007 Dec;17(6):400-9. doi: 10.1097/CMR.0b013e3282f1d312. Melanoma Res. 2007. PMID: 17992124 Review.
-
Free radicals, metals and antioxidants in oxidative stress-induced cancer.Chem Biol Interact. 2006 Mar 10;160(1):1-40. doi: 10.1016/j.cbi.2005.12.009. Epub 2006 Jan 23. Chem Biol Interact. 2006. PMID: 16430879 Review.
-
Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.Melanoma Res. 2010 Feb;20(1):11-20. doi: 10.1097/CMR.0b013e328334131d. Melanoma Res. 2010. PMID: 19966593
-
Reactive oxygen species: an Achilles' heel of melanoma?Expert Rev Anticancer Ther. 2008 Nov;8(11):1751-7. doi: 10.1586/14737140.8.11.1751. Expert Rev Anticancer Ther. 2008. PMID: 18983235 Review.
-
Influence of therapy on the antioxidant status in patients with melanoma.J Clin Pharm Ther. 2008 Apr;33(2):179-85. doi: 10.1111/j.1365-2710.2008.00909.x. J Clin Pharm Ther. 2008. PMID: 18315784 Clinical Trial.
Cited by
-
Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial.Cancer Prev Res (Phila). 2022 Jun 2;15(6):365-375. doi: 10.1158/1940-6207.CAPR-21-0244. Cancer Prev Res (Phila). 2022. PMID: 35395069 Free PMC article. Clinical Trial.
-
Cutaneous melanoma in women.Int J Womens Dermatol. 2017 Feb 16;3(1 Suppl):S11-S15. doi: 10.1016/j.ijwd.2017.02.003. eCollection 2017 Mar. Int J Womens Dermatol. 2017. PMID: 28492033 Free PMC article. Review.
-
Assessing the quality of care for skin malignant melanoma on a global, regional, and national scale: a systematic analysis of the global burden of disease study from 1990 to 2019.Arch Dermatol Res. 2023 Dec;315(10):2893-2904. doi: 10.1007/s00403-023-02730-2. Epub 2023 Sep 29. Arch Dermatol Res. 2023. PMID: 37773351 Free PMC article. Review.
-
Sex and Gender Disparities in Melanoma.Cancers (Basel). 2020 Jul 7;12(7):1819. doi: 10.3390/cancers12071819. Cancers (Basel). 2020. PMID: 32645881 Free PMC article. Review.
-
Gender Differences and Outcomes in Melanoma Patients.Oncol Ther. 2020 Jun;8(1):103-114. doi: 10.1007/s40487-020-00109-1. Epub 2020 Feb 4. Oncol Ther. 2020. PMID: 32700073 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical